Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Table 2 Base-Case Value and Sensitivity Range for Costs

Variables	Base case value	Range
Costs in China($)
Monthly cost of sorafenib and TACE
Full-dose Sorafenib
The first 3 months without supportive policy⁴⁸	7600.38	3800.19–15,200.76
3 months after⁴⁸	15.06	7.53–30.11
Dose-adjusted Sorafenib
The first 3 months without supportive policy⁴⁸	3807.72	1903.86–7615.43
3 months after⁴⁸	15.06	8.03–32.11
TACE per session	3347.97	1673.99.23–6695.95
Monthly cost of progressive HCC^#	247.43	123.71–494.86
Monthly cost of decompensated cirrhosis^a,b	1131.82	565.91–2263.65
Monthly cost of compensated cirrhosis^a,b	344.14	172.07–688.29
Costs in the USA($)
Monthly cost of sorafenib and TACE
Full-dose Sorafenib
The first 3 months without supportive policy⁵⁰	4592.4	2296.2–9184.8
3 months after⁵⁰	1.2	0.60–2.40
Dose-adjusted Sorafenib
The first 3 months without supportive policy⁵⁰	2296.2	1148.10–4592.40
3 months after⁵⁰	1.2	0.60–2.40
TACE per session⁴⁹	25,961.00	12,980.50–51,922.0
Monthly cost of progressive HCC^51#	8072	4036.00–16,144.00
Monthly cost of decompensated cirrhosis^49#	1519.0	759.50–3038.00
Monthly cost of compensated cirrhosis^49#	61.0	30.0–122.00

^aThe data were obtained from the large HCC database of South China (http://hcc.medidata.cn/)
^bThe total monthly cost of drugs and procedures (that include treatments for HCC, cirrhosis and adverse events derived from associated drugs and procedures), inpatient and outpatient visits, laboratory testing and imaging examination

ISSN: 1471-2407